Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502237 · ClinicalTrials.gov registry record · Phase 3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 1,021
- Enrollment target
- 20
- Study locations
NCT05502237 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 1,021 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05502237, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,021 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (20)
Other
- Investigaciones CORI S.R.L. - Capital
- Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica - Cardoba
- Sanatorio Allende - Córdoba
- Sanatorio Britanico de Rosario - Rosario
- Sanatorio Parque de Rosario - Rosario
- Hospital Provincial del Centenario - Rosario
- Instituto Medico de la Fundacion Estudios Clinicos - Rosario
- Clínica Viedma - Viedma
- Ordensklinikum Linz GmbH, Elisabethinen - Linz
California
- Innovative Clinical Research Institute - Whittier
District of Columbia
- George Washington Medical Faculty Associates - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Illinois Cancer Care - Peoria
North Carolina
- Messino Cancer Centers - Asheville
Ohio
- Oncology Hematology Care, Inc. - Cincinnati
Oregon
- Hematology & Oncology Associates - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,021 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05502237
The ClinicalTrials.gov registry entry for NCT05502237 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,021 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05502237 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05502237 about?
NCT05502237 is a clinical study titled "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer". The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer wit...
What is the current status of trial NCT05502237?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,021 participants. The study started on 2022-10-12. Estimated completion is 2029-01.
What conditions does trial NCT05502237 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05502237?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT05502237?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502237 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.